|
|
|
For more press releases, please click here.
Agendia’s MammaPrint® Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
Thursday, 18 September 2008
HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, September 18, 2008 -- Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint®, has been included in the updated 2008 guidelines of The Dutch Institute for Healthcare Improvement CBO. The CBO guidelines, which ...
Read more |
Agendia Launches TargetPrint for Breast Cancer Patients
Optimizing Patient Identification for Targeted Therapies
That Ensure Benefits of Personalized Treatment
Thursday, 04 September 2008
HUNTINGTON BEACH, CA, and AMSTERDAM, The Netherlands, September 4, 2008 / Agendia, a world leader in molecular cancer diagnostics, today announced the launch of TargetPrint®, a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor (ER), progesterone receptor (PR) and Human ...
Read more |
Agendia and Ferrer announcs exclusive agreement for sales of cancer diagnostic services in four major european markets
Tuesday, 15 July 2008
AMSTERDAM, The Netherlands and BARCELONA, Spain, July 15, 2008 / Agendia BV and Ferrer inCode today announced an agreement that will give Ferrer exclusive rights to sell two of Agendia’s signature cancer diagnostic services.
MammaPrint, a prognostic test that uses a 70-gene signature to indicate risk of breast cancer tumor recurrence, ...
Read more |
Agendia expands laboratory capacity at new amsterdam headquartes to meet increasing demand for services worldwide
Thursday, 19 June 2008
AMSTERDAM, The Netherlands, June 19, 2008 / Agendia BV has announced the official opening of the company's new headquarters yesterday at Amsterdam's Science Park at Watergraafsmeer, Kruislaan 406. The Grand Opening ceremony was officiated by Dr. Rene Bernards, Chief Scientific Officer at Agendia and the Honourable Director General Mrs. ...
Read more |
MammaPrint Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions
Friday, 30 May 2008
CHIGACO, USA, May 30, 2008 / Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, announced today that data from two studies involving its MammaPrint breast cancer prognosis test will be presented at the American Society of Clinical Oncology’s (ASCO) annual meeting. Collectively, these findings ...
Read more |
|
|
|
About Agendia